ArticleArchives of medical science : AMS2026
Plasma proteome-genome integration reveals novel protein biomarkers and therapeutic targets linked to breast cancer survival.
Article in Archives of medical science : AMS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Identifying new drug targets is essential for improving breast cancer survival. The proteome provides a rich source for potential therapeutic targets. This study aimed to identify protein markers and therapeutic targets for breast cancer by using proteome-wide Mendelian randomization (MR). Material and methods: Protein quantitative trait loci (pQTL) data were obtained from four large-scale proteomic studies, including 17,267 circulating protein markers. Genetic associations with breast cancer survival were derived from a large-scale GWAS meta-analysis (37,954 cases, 2,900 deaths). Proteome-wide MR was performed to estimate causal effects of proteins on breast cancer survival, complemented by single-cell expression analysis to identify enriched cell types. Protein-protein interactions (PPI) and druggability assessments were also conducted to prioritize therapeutic targets. Results: Genetically predicted circulating levels of 27 proteins were found to be associated with breast cancer survival. Among these, eight proteins (ADAM15, CD83, SH3BGRL3, SNCG, ANXA1, GRHPR, ALDH2, and MTHFD2) showed the strongest evidence of association, while four proteins (ARG2, RPL14, NFU1, and TXNL4B) demonstrated a strong but slightly weaker correlation. Notably, SH3BGRL3, GRHPR, ARG2, RPL14, NFU1, and TXNL4B were newly identified as circulating protein markers significantly associated with breast cancer prognosis. Druggability analysis revealed that 13 of these proteins were already targeted by existing drugs, offering potential for breast cancer treatment. Conclusions: We identified 27 genes encoding proteins associated with overall and subtype-specific breast cancer survival, providing potential prognostic biomarkers and therapeutic targets, and offering new avenues for improving breast cancer management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.